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Abstract 
Poor aqueous solubility is often linked with a poor dissolution rate and ultimately, limited 
bioavailability of pharmaceutical compounds. This study describes the application of 
mesoporous materials (Syloid 244 and Syloid AL1) in improving the dissolution rate of a 
drug with poor aqueous solubility, namely artemether, utilising different processing 
methods including physical mixing, co-grinding and solid dispersions prepared by solvent 
evaporation and the lyophilisation technique. The prepared formulations were extensively 
characterised for their solid-state properties and the drug release attributes were studied. 
Differential scanning calorimetry and X-ray diffraction confirmed conversion of 
crystalline artemether into a disordered and amorphous form, while no intermolecular 
interactions were detected between artemether and silica. Both silica grades enhanced the 
dissolution rate of artemether in comparison with drug alone, for example from 17.43% 
(± 0.87 %) to 71.55 % (±3.57 %) after 120 mins with lyophilisation and Syloid 244 at a 
1:3 ratio. This enhancement was also dependant on the choice of processing method, for 
example, co-ground and lyophilised formulations prepared with Syloid 244 at 1:3 ratio 
produced the most extensive dissolution, thus endorsing the importance of materials as 
well as choice of formulation method.  
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1. Introduction 
Despite several possible options for routes of administration, the oral route is most 
preferable, mainly because of patient ease in ingesting drugs and for economic reasons. 
Nevertheless, orally administered drugs must dissolve in biological fluids before reaching  
the target site. It is estimated that more than 70 % of investigational new drugs exhibit poor 
aqueous solubility and limited dissolution (Kawabata et al., 2011), thus causing difficulty for 
pharmaceutical researchers with regards to formulation, i.e. to ultimately make them 
available at the bedside (Lipinski, 2002). Poor aqueous solubility impedes in vivo efficacy of 
drugs by presenting limited bioavailability, a poor pharmacokinetic-profile, increased 
subject-to-subject and inter-species variation, all of which results in potential drug candidates 
being rejected from formulation in suitable dosage forms (van de Waterbeemd, 1998). In 
recent years, various techniques have been proposed to address the poor solubility issue 
including physical and chemical approaches, such as modification of crystal habits (Blagden 
et al., 2007), lipid formulations (Humberstone and Charman, 1997), cyclodextrin 
complexations (Challa et al., 2005), salt or co-crystal formations (Elder et al., 2013), use of 
solubilising agents, pro-drug formation (Fleisher et al., 1996), solid dispersions (Brough and 
Williams, 2013; Shahzad et al., 2013), micronisation and nanosization (Chaumeil, 1998; 
Chen et al., 2011; Müller et al., 2001). All of these methods and techniques have certain 
benefits and limitations; such as the selection of an appropriate method depends upon the 
physicochemical properties of the active pharmaceutical ingredient (API).  
The poor aqueous solubility of most APIs is believed to be a result of their high lattice 
energy within the crystalline structure (Thomas et al., 2014). Thus, any technique involving 
reduction in lattice energy, by converting from a crystalline to amorphous state, may 
significantly enhance solubility and dissolution. However, purely amorphous drugs are rarely 
formulated commercially as such in dosage forms, rather they are blended with amorphous 
excipients, which stabilise the amorphous form of the drug during storage and inhibit 
recrystallisation during the dissolution phase (Van den Mooter, 2012). The amorphous solid 
dispersion (ASD) is an interesting approach that can increase apparent solubility without 
causing a concomitant decrease in apparent permeability as seen with other solubility 
enhancing techniques, for example, co-solvent solubilisation which improves solubility yet 
permeability and bioavailability are compromised (Ueda et al., 2012).  
Highly porous and amorphous mesoporous silicas are gaining notable attention  because 
of their potential  application in medicine, biosensors, drug-delivery, catalysis, thermal 
energy storage and imaging (Giraldo et al., 2007). Mesoporous silica has a pore diameter of 
  
2-50 nm and classified as ordered and non-ordered, both of which are  used as potential 
carriers for enhancing solubility and dissolution of poorly soluble drugs (McCarthy et al., 
2016; Qian and Bogner, 2012; Xu et al., 2013). Mesoporous silica materials are nontoxic, 
biocompatible and biologically safe. Furthermore, amorphous silicas are degradable in living 
tissue and excreted from the body as orthosilicic acid (Martin, 2007). Mesoporous materials 
can be used in their native form or following modifications, including purpose-built 
functionalisations that have resulted in desireable pharmaceutical properties, thus improving 
both in-vitro and in-vivo profiles of drugs (Vinu et al., 2005).  
Structurally, ordered silica has a more uniform and intricate pore structure in comparison 
with non-ordered mesoporous silica (Hussain et al., 2017). However, they possess a similar 
surface chemistry, consisting of siloxane and silanol groups (Zhuravlev, 2000) that may 
associate with the loaded substances to form hydrogen-bonds (Bahl and Bogner, 2006). The 
advantages of mesoporous materials as  drug delivery vehicles can be attributed to their large 
effective surface area and pore volume, which are known to contribute towards greater drug 
loading, prevention of premature degradation and promotion of tuned and fast drug release 
(Xu et al., 2013). The amorphicity of drug in silica solid dispersions is simply a result of 
adsorption on the surface of silicates (Watanabe et al., 2001; Waters et al., 2013) and 
confinement/entrapment/capillary condensation of drugs in mesopores (Waters et al., 2013). 
Once drug is loaded in mesopores, the drug can stay in an amorphous or molecularly 
dispersed state as a result of spatial constraints of the silica pores that inhibits drug nucleation 
and crystal growth (Laitinen et al., 2013; Prinderre, 2015). Drug loading methods also 
account for the enhanced performance of formulations prepared with mesoporous silicas 
(Qian and Bogner, 2012). 
Herein, we report the effect of processing methods on the drug release behaviour of a 
poorly water-soluble compound, namely artemether, from mesoporous silica. Artemether 
(Fig.1) is a crystalline drug used as an antimalarial agent that kills malarial parasites by 
alkylating biomolecules through free radical formation (Meshnick, 2002). Artemether also 
has the potential to kill cancerous cells (Humphreys et al., 2016). Two grades of silica were 
employed in preparing formulations encompassing four different methods, namely physical 
mixing, co-grinding, solvent evaporation and lyophilised solid dispersions. Formulations 
were extensively characterised using a variety of analytical tools in order to study solid-state 
properties. This was followed by an investigationof drug release behaviour inan acidic 
dissolution media in the hope that modifications to the formulation will enhance the drug 
release profile.  
  
 
 
 
 
 
 
 
 
Fig. 1: Chemical structure of artemether 
 
2. Materials and methods 
 
Artemether with a minimum purity of 98 % was received as a gift sample from Hamaz 
Pharmaceuticals (Multan, Pakistan). Grace Discovery Sciences (Pune, India) generously 
gifted Syloid® 244 FP and Syloid® AL1/63FP silica. Ethanol was sourced from Sigma-
Aldrich (Dorset, UK). Distilled water (prepared at an in-house facility) was used throughout 
the experiments. 
2.1.Physical mixing of drug with silicas 
Artemether was tumble mixed with two different Syloid silica samples (Syloid 244 and 
Syloid AL1) at 1:0.5, 1:1 and 1:3 drug to silica ratios for 5 minutes to ensure homogenous 
mixtures were achieved. The physical mixtures (PM) were stored in airtight containers until 
further use. 
2.2.Co-grinding of drug with silicas 
Samples initially underwent tumble mixing, as described in Sec. 2.1. Following this, 
samples were subjected to moderate unidirectional grinding in a pestle and mortar for 10 
minutes to hopefully achieve complete (or partial) amorphisation of artemether. The co-
ground (CG) mixtures were sieved through a number 60 mesh and stored in airtight 
containers until further use.  
2.3.Solvent evaporated and lyophilised solid dispersions 
Solid dispersions were prepared by solvent evaporation and lyophilisation techniques. 
For solvent evaporated (SE) solid dispersions, an accurately weighed quantity of artemether 
was dissolved in 10 mL of ethanol. To this solution, each silica at a specified drug to silica 
ratio (1:0.5, 1:1 and 1:3) was added and the mixture was left stirring for 10 minutes. 
  
Afterwards, the mixtures were oven dried at 40 °C to ensure removal of residual ethanol, i.e. 
until samples reached a constant weight. The resultant dry powder was sieved through a 
number 60 mesh and the solid dispersions were stored in airtight containers until further 
investigation.  
For lyophilised dispersions (FD), a weighed quantity of drug was dissolved in a 10 % 
v/v ethanol-water mixture until a clear solution formed. Silica samples were then introduced 
to the solution at specified drug to silica ratios (1:0.5, 1:1 and 1:3). Each mixture  of Syloid 
244 and Syloid AL-1FP, at three drug to silica ratios, was frozen at -10 °C , followed by 
lyophilisation (EYELA Freeze-Dryer FD-550) at -42 °C and vacuum of ~0.100 mBar, in 
order to completely remove the solvent. The resultant freeze-dried mixtures were gently 
triturated and then passed through a sieve no. 60 before storing in airtight containers (Ansari 
et al., 2015). 
2.4.Characterisation of formulations 
2.4.1. Differential scanning calorimetry (DSC) 
Thermal analysis of the samples was conducted using DSC (SDT Q600, TA Instruments, 
USA). Accurately weighing 2-8 mg  samples were placed in flat-bottomed aluminum 
crucibles. The crucibles were crimped and pierced before placing in the DSC . Samples were 
heated from 30 °C to 300 °C at a heating rate of 10 °C/min under a dry nitrogen purge 
flowing at 40 mL/min. 
2.4.2. X-Ray powder diffraction (XRD)  
XRD patterns of formulations were obtained using an X-Ray Diffractometer (PANalytical 
X’Pert Pro powder, The Netherlands) equipped with a CuKα radiation source (1.5406 Å) 
with a generator voltage and current of 30 kV and 10 mA, respectively. Samples were 
mounted on plate holders and the diffraction patterns were measured in ambient conditions 
by scanning in the 2θ range of 5-50 ° with a step size of 0.02.  
2.4.3. Attenuated total reflectance-Fourier transform Infra-red spectroscopy (ATR-
FTIR) 
The infrared spectrum of pure artemether and formulations were obtained through ATR-
FTIR spectrophotometry (Agilent technologies Cary 600 series) by scanning from 400-4000 
cm-1 wavelength range at 2 cm-1 resolution in the transmittance mode. The instrument 
calibration was occasionally repeated during these operations. 
2.4.4. Scanning electron microscopy (SEM) 
  
The morphology of formulations was analyzed using SEM (JSM-5910, JEOL, Japan). 
Samples were lightly spread over specimen stubs after sputter coating with gold and images 
at different magnifications were captured at an accelerating voltage of 10-15 kV energy. 
2.5.Spectrophotometric quantification of artemether 
Spectrophotometric quantification of artemether  (ART) was performed using the World 
Health Organisation (WHO) prescribed method (WHO, 2016). Briefly, accurately weighed 
50 mg samples of ART were dissolved in sufficient dehydrated ethanol to produce a final 
volume of 100 mL. 20 mL of this solution was diluted to 100 mL with hydrochloric 
acid/ethanol (1 mol/L) mixture to achieve an artemether concentration of 100 μg/mL. This 
solution was heated at 55 °C for 5 h in a water bath and allowed to cool to room temperature. 
Sufficient quantities were withdrawn from the stock solution to make a series of dilutions 
with HCl/ethanol (1 mol/L), to achieve concentrations of 50, 40, 20, 10, 5, 3.125, 1.56, and 1 
μg/mL. The absorbance of dilutions was measured at 254 nm using a UV spectrophotometer 
(HALO DB-20, Dynamica, Australia) and a calibration plot was constructed. 
 
2.6.In-vitro dissolution studies 
Dissolution studies were performed on pure artemether, physical mixtures, co-ground 
mixtures and the solid dispersions prepared by solvent evaporation and lyophilization using 
USP type II dissolution apparatus. A 20 mg drug equivalent sample of each formulation was 
added to the dissolution bath filled with 500 mL of freshly prepared 0.1N HCl solution (pH 
1.2). The temperature of the bath was set at 37 °C (±0.5 °C) and the paddles were rotated at 
50 rpm. At predetermined time intervals of 5, 10, 15, 20, 25, 30, 60 and 120 minutes, 5 mL 
samples were withdrawn with a syringe fitted with a 0.45μm syringe filter, and immediately 
replenished with 5 mL of fresh 0.1N HCl solution to ensure perfect sink conditions existed 
throughout the experiment. The withdrawn samples were analysed using a UV-
spectrophotometer set at a wavelength of 254 nm. All experiments were repeated in 
triplicatewhereby drug release was quantified based on a series of standard solutions at 
known concentrations. 
 
3. Results and discussion 
3.1.Solid-state characterisation 
Solid-state properties of pure artemether and formulations were studied using a 
variety of analytical tools including DSC, XRD, ATR coupled FT-IR and SEM. These 
  
powerful analytical tools were used to help characterise various physical and chemical 
properties of artemether in the formulations. 
DSC thermograms of pure artemether and selected physical mixtures, co-ground 
mixtures, solvent evaporated and lyophilised solid dispersions prepared with two grades of 
mesoporous silica are presented in Fig.2. Artemether is a crystalline compound having a 
melting point of 86 - 90°C (WHO, 2016). DSC thermograms of pure artemether showed an 
endothermic melting peak appearing at 90 °C followed by a larger and broader exothermic 
peak appearing at 172 °C. The appearance of the melting peak confirmed the crystallinity of 
artemether. All formulations prepared at 1:0.5 drug to silica ratios showed characteristic 
artemether melting peaks without any polymorphic transition (DSC data not shown for 1:0.5 
and 1:1 ratios). However, there was a gradual decrease in the intensity of the melting peak 
with increasing silica content in the formulations, and no melting peak was detected when the 
silica content reached a maximum (1:3 drug to silica ratio), as exemplified in Fig. 2. The 
melting point depression, and even disappearance, could be a result of complete pore 
confinement of artemether within the mesopores of both silica grades, or the drug may have 
transformed to an amorphous form (Salonen et al., 2005; Xu et al., 2013). The approximate 
diameter of an artemether molecule is 0.83 nm, as shown in Fig.1. This is sufficiently smaller 
than the average pore diameter of 16 nm for Syl 244 and 2.9 nm in the case of Syl AL1. 
Thus, pore confinement of drug is inevitable and attenuation of the  melting peak in DSC 
thermograms confirms this. In the case of physical mixtures, the absence of a melting peak 
possibly relates to drug adsorption on the silica surface in an amorphous form. This 
phenomenon has been seen in a previous study whereby a highly hydrophobic drug, namely 
gemfibrozil, showed almost no melting peak at the highest drug to silica ratio (Hussain et al., 
2017). The change in the physical state of drug can also be explained on the basis of possible 
interaction of silanol groups present on the surface of mesoporous silica with the functional 
groups of drug that may have resulted in hydrogen bonding between them, thus reducing the 
drug’s crystallinity and promoting amorphicity (Gupta et al., 2002). 
 We were also interested to see how co-grinding may affect the thermal properties of 
artemether. The co-ground samples showed a prominent decrease in the peak intensity with 
increasing silica content, and the melting peak was even absent in the 1:3 co-ground 
mixtures. This was a result of the reduction in particle size of artemether from grinding. This 
opens up another possibility of drug being entrapped within the mesopores, or maybe 
adsorbed on the silica surface, in molten form from shear grinding force. The exact 
mechanism is still enigmatic, thus warrants further study.  
  
 
Fig. 2. DSC thermograms of artemethe (left) and selected formulations (right) with two 
grades of silica i.e. a) Syl 244 PM(1:3), b) Syl AL1 PM(1:3), c) Syl 244 CG(1:3), d) Syl AL1 
CG(1:3), e) Syl 244 SE(1:3), f) Syl AL1 SE(1:3), g) Syl 244 FD(1:3), and h) Syl AL1 
FD(1:3). 
 
Wide-angle X-ray diffraction is a robust technique to identify crystallinity of a 
material. The XRD pattern of pure artemether and the formulations (PM, CG, SE and FD) 
formulated with Syl 244 and Syl AL1 at ratios of 1:0.5 and 1:3 are presented in Fig. 3. The 
pure artemether displayed several diffraction peaks appearing at 9.72°, 10.23°, 17.91°, 
19.55°, thus confirming the crystalline nature of the drug. In comparison to pure artemether, 
all the samples including PM, CG, SE and FD prepared with either Syl 244 or Syl AL1 
displayed drug peaks at the lowest silica content (1:0.5), indicatingartemether was 
predominantly in its crystalline form. However, the diffraction peaks were absent in the 
formulations with a higher silica content (1:3). This confirms the conversion of crystalline 
drug into a more disordered or amorphous form, and possibly the drug may have become 
entrapped in the pores. The XRD results are in complete agreement with the DSC results 
(Fig. 2). However, formulation Syl AL1 FD(1:3) showed a diffraction peak with reduced 
intensity, which means the drug might have recrystallised on the surface of Syloid AL1 silica. 
This could be attributed to the large surface area (605 m2/g) and small pore size/volume 
(2.9nm/0.3cm3/g) of Syl AL1 as compared with Syl 244 (Hussain et al., 2017). The 
recrystallisation of drug is also reflected by a small melting peak that appeared in the freeze-
dried sample (Syl FD(1:3), as can be seen in Fig. 2h. 
 
  
 
Fig. 3. XRD patterns of ART and formulations using physical mix method and co-grinding 
method. 
 
The stability of formulations were assessed under stressed conditions for three months, 
and no significant change in the XRD and DSC patterns were observed (data not shown), thus 
endorsing the stability of formulations. 
 
Infrared spectroscopy is helpful in elucidating possible drug-excipient interactions, and 
was therefore applied to this study to investigate interactions between artemether and Syloid 
silica in various formulations. Fig. 4 illustrates FT-IR spectra of pure artemether, PM, CG, 
SE and FD formulations at 1:1 drug to silica ratios. Characteristic artemether peaks were 
observed at 1250.4 cm-1 for C-O stretching vibrations, 1450.1 cm-1 for C-H bending, 1024.9 
cm-1 and 1277.8 cm-1 for C-O-C stretching vibrations, and a peak at 1121.5 cm-1 for C-O-O-C 
bending vibrations, which is an endoperoxide bridge and responsible for pharmacological 
activity of artemisinins. In the functional group region, four characteristic peaks of C-H 
  
stretching vibrations appeared at 2938.4 cm-1, 2915.1 cm-1, 2874.8 cm-1 and 2845.6 cm-1. FT-
IR spectra of Syloid showed a silanol bending band appearing at 950 cm-1, which remains 
unshifted in the IR spectra of formulations, thus endorsing no observable intermolecular 
interaction. On the other hand, characteristic artemether peaks with much reduced intensities 
were observed without a shift in the IR spectra of formulations, thus, it is plausible that the 
drug was efficiently loaded into mesoporous silica in a partial or completely amorphous form.  
 
 
 
Fig. 4. FT-IR spectra of artemether, Syloid, and selected formulations. 
 
SEM images were taken to assess the surface morphology of silica and formulations 
(CG, SE and FD) and the images are presented in Fig. 5. Artemether is a crystalline 
compound as can be seen in Fig. 5(A), SEM image courtesy of  Fule and co-workers (Fule et 
al., 2013). Co-ground mixtures prepared with Syl 244 or Syl AL1 (1:3) showed an even 
distribution of silica particles with artemether particles reduced in size Fig. 5D and G. The 
drug appeared to be more amorphous in the solvent evaporated (Fig. 5E) and freeze-dried 
(Fig. 5F) solid dispersions prepared with Syl 244, as confirmed with DSC and XRD results. 
Apart from pore confinement of drug into Syl AL1 silica, small crystals of drug also appeared 
to be adsorbed on the surface of Syl AL1 solid dispersions prepared by the solvent 
evaporation and lyophilisation methods, as depicted in Fig. 5H and I. This could be a 
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consequence of the small pore diameter/volume and larger surface area of Syl AL1 compared 
with Syl 244. 
 
 
Fig. 5. SEM images of (A) artemether, (B) Syloid 244, (C) Syoid AL1, (D) Syl 244 CG(1:3), 
(E) Syl 244 SE(1:3), (F) Syl 244 FD(1:3), (G) Syl AL1 CG(1:3), (H) Syl AL1 SE(1:3), and 
(I) Syl AL1 FD(1:3). 
  
3.2.In-vitro dissolution studies 
In-vitro dissolution studies are designed for the biopharmaceutical screening of 
formulations. As oral formulations are required to disperse in the stomach contents, 
dissolution measurement in acidic media can provide a good initial estimate of dissolution 
extent and rate enhancement. The in-vitro dissolution profiles of pure artemether, physical 
mixtures, co-ground mixtures, and solvent evaporated and lyophilised solid dispersions are 
presented in Fig.s 6 and 7. Overall, the amounts of silica and the processing method appeared 
to influence the dissolution rate of artemether. Pure artemether only dissolved 17.43% (± 0.87 
  
%) in the dissolution media over the course of 120 minutes. Whilst a significant increase in 
the dissolution of artemether was observed with both silica grades and with each processing 
method. 
 Physical mixtures (PM) with Syl 244 released more drug (33.98 ± 1.6 %) for 1:0.5 
ratio, whilst 1:1 and 1:3 ratios released 58.32 % (± 2.91 %) and 57.70% (± 2.88 %) of drug in 
the course of 120 min, respectively. For co-ground samples (CG), drug release after 120 min 
was 35.72% (± 1.78 %) for 1:0.5 ratio, 54.28% (± 2.71 %) for 1:1 ratio, and 71.01% (± 3.55 
%) for 1:3 ratio. In the case of solvent evaporated solid dispersions (SE), 33.55 % (± 1.68 %) 
drug was released from the 1:0.5 ratio, 23.90 % (± 1.19 %) from the 1:1 ratio, and 30.48 % (± 
1.52 %) from ?. For lyophilised solid dispersions (FD), the extent of drug release after 120 
min was 32.56 % (± 1.63 %), 31.76 % (± 1.58 %) and 71.55 % (± 3.57 %) for 1:0.5, 1:1 and 
1:3 ratios, respectively. Overall, drug release was superior from Syl 244 processed 
formulations, compared with pure artemether. Syl 244 CG(1:3) and Syl 244 FD(1:3) 
formulations produced the greatest release, followed by the Syl PM(1:3) formulation. More 
interestingly, an initial burst release was observed with CG(1:3) and FD(1:3) formulations 
with more than 50 % of drug released in the first 30 min of dissolution. This initial burst 
release of drug could stem from the fact that drug may have adsorbed on the surface or 
confined in the external pores present on the surface of silica. Whilst slower and sustained 
release is expected when the drug is entrapped deep in pores (Xia et al., 2012). The later 
phenomenon was evident in the solvent evaporated solid dispersions, and the drug release 
was slower and in a more controlled fashion.  
The second silica grade, namely Syloid AL1 considered in this study also enhanced 
artemether dissolution, however, to a lesser extent as compared with Syloid 244. More 
importantly, the extent of drug release gradually decreased with increasing silica content in 
the case of PM and CG samples. With physical mixtures, the greatest drug release achieved 
was 40.50 % (± 2.02 %) for Syl AL1 PM(1:0.5), while 32.27 % (± 1.61 %) and 20.93 % (± 
1.04 %) drug release was achieved for 1:1 and 1:3 ratios after 120 mins. Co-ground sample at 
1:05 ratio released about 32 % of drug in 120 min dissolution run, which further decreased to 
31 % and 22 % for 1:1 and 1:3, respectively. However, the opposite trend was observed in the 
solvent evaporated and lyophilised solid dispersions, with an exception of Syl AL1 SE(1:1), 
which produced the greatest drug release (55.74 ± 2.78%) after 120 mins. Drug release 
increased from 32 % to 48 % with increasing Syl AL1 content in the case of lyophilised solid 
dispersions (FD).  Greater dissolution was achieved  with SE and FD formulations in 
comparison with PM and CG, this could stem from the fact that surface adsorption and pore 
  
confinement is likely to be higher with loading methods involving organic solvents. When the 
formulation comes in contact with the polar solvent (the dissolution medium), the drug leaves 
the surface of silica more abruptly owing to interactions between polar solvent molecules and 
silanol groups available on the silica surface (Charnay et al., 2004; Fernández-Núñez et al., 
2009). 
Overall, a superior drug release was achieved with both silica grades as compared 
with pure drug. The contributing factors in enhancing the drug release are possibly the extent 
of drug’s amorphicity and the surface properties including the pore size, pore volume and 
available surface area. With Syloid 244, drug release was much higher and faster as 
compared with Syloid AL1. The Syloid 244 silica has a much smaller particle size than 
Syloid Al-1 silica, therefore diffusion of solvent/dissolution media into pores is expected to 
be more rapid as path length is shorter, thus quickly dispersing nanosized drug molecules, 
resulting in enhanced dissolution (Limnell et al., 2011).  
 
 
 
 
 
Fig. 6. Dissolution profiles of artemether and Syloid 244 processed formulations  
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Fig. 7. Dissolution profiles of artemether and Syloid AL1 processed formulations 
 
3.3. Kinetic release mechanism 
To understand the kinetic mechanisms of drug release from porous silica particles, 
Higuchi and Krosmeyer-Peppas kinetic models were fitted to the dissolution data (Peppas, 
1985). The best-fit model was selected based on regression coefficient (R2) value and the 
corresponding n value in Krosmeyer-Peppas model defined the mechanism (Fickian/non-
Fickian or anomalous). Krosmeyer-Peppas was found to be best model describing the drug 
release mechanism in our study. Fickian diffusion was the main kinetic mechanism of drug 
release in the case of Syl 244 PM(1:0.5) and Syl 244 PM(1:1). The remaining formulations 
displayed a non-Fickian diffusion, or anomalous, drug release behaviour. 
 
4. Conclusions 
In this manuscript, we report the impact of processing methods on the dissolution of a 
poorly aqueous soluble drug, namely artemether, utilising two grades of silica. Various 
formulations were created including physical mixtures, co-ground mixtures, solvent 
evaporated and lyophilised solid dispersions. The formulations were extensively 
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characterised for their solid- state properties and in-vitro dissolution behaviour was studied. 
Interestingly, the processing method utilised and the type of silica appeared to influence the 
physicochemical properties of artemether. With increasing silica content, the drug 
amorphicity increased as confirmed by DSC and XRD, whilst intermolecular interactions 
were absent as confirmed by FT-IR. SEM images confirmed uniform mixing of artemether 
with silica, whereas some crystalline drug was also visualised in solvent evaporated and 
lyophilised solid dispersions prepared with Syloid AL1. Both silica grades (Syloid 244 and 
Syloid AL1) increased the dissolution rate of artemether; however, this enhancement was 
more prominent with Syloid 244. The co-ground mixture and lyophilised dispersion prepared 
at 1:3 ratio using Syloid 244 enhanced drug dissolution the most. On the contrary, dissolution 
decreased with increasing concentration of Syloid AL1 for physical and co-ground mixtures. 
The drug release mechanism was found to be predominantly non-Fickian. Overall, a more 
controlled and precise drug release can be achieved through a judicious choice of excipients 
and processing methods.  
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